Dashboard
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 2.37% of over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times
Risky - Negative EBITDA
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Commodity Chemicals
INR 42 Cr (Micro Cap)
NA (Loss Making)
21
0.00%
0.49
-7.84%
2.64
Total Returns (Price + Dividend) 
Shreyas Interm. for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
Announcements 
Closure of Trading Window
30-Mar-2026 | Source : BSEPursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations 2015 as amended from time to time and Shreyas IntermediateS limiteds Code of Conduct for Insiders the Trading Window for dealing in securities of the Company shall remain close for designated persons (as defined in the code) including their immediate relatives w.e.f. 01.04.2026 till 48 hours after the announcement of the Audited Financial Results for the quarter and year ended 31.03.026.
Announcement under Regulation 30 (LODR)-Newspaper Publication
17-Feb-2026 | Source : BSENewspaper cuttings in connection with the UFR for the quarter ended 31.12.2025 in terms of Regulation 30 & 47 of SEBI (LODR) Regulations 2015.
Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting For Meeting Held On 13.02.2026
13-Feb-2026 | Source : BSEIn terms of Regulations 30 and 33(3) of SEBI (LODR) Regulations 2015 this is to inform that the Meeting of the Board of Directors of the Company was held today on 13th February 2026 Friday at the registered office of the Company at 4:00 p.m. and concluded at around 05.00 p.m. The Board inter-alia considered and approved the following matters. 1.The Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2025 along with Limited Review Report thereon pursuant to Regulation 33 of SEBI (LODR) Regulations 2015. 2.Took note on Compliances made under SEBI (LODR) Regulation 2015 for the quarter and nine months ended 31st December 2025.
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Promoters
10.028
Held by 3 Schemes (0.0%)
Held by 1 FIIs (8.39%)
Kesar Petroproducts Limited (27.59%)
Krish Pharma Speciality Private Limited- Escrow Demat Accoun (24.7%)
7.82%
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ
QoQ Growth in quarter ended Dec 2025 is -100.00% vs 64.08% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -62.50% vs 29.41% in Sep 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024
Growth in half year ended Sep 2025 is 36.26% vs -8.33% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 23.62% vs 11.81% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024
YoY Growth in year ended Mar 2025 is -0.63% vs -0.64% in Mar 2024